Jazz Pharmaceuticals JAZZ Modeyso — Revenue from Contract with Customer, Excluding Assessed Tax
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Jazz Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The official record: Jazz Pharmaceuticals’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Jazz Pharmaceuticals's modeyso — revenue from contract with customer, excluding assessed tax.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Jazz Pharmaceuticals's modeyso — revenue from contract with customer, excluding assessed tax?
- Jazz Pharmaceuticals (JAZZ) reported modeyso — revenue from contract with customer, excluding assessed tax of $41.4M in Q1 2026.
- What does modeyso — revenue from contract with customer, excluding assessed tax mean?
- The total net sales revenue generated specifically from the Modeyso product line.
- How do you interpret modeyso — revenue from contract with customer, excluding assessed tax?
- An increase indicates successful market penetration, higher prescription volume, or effective pricing strategies for the product, while a decrease may signal competitive pressure, loss of market share, or declining demand.
- How does modeyso — revenue from contract with customer, excluding assessed tax compare across companies?
- Comparable to product-specific net revenue line items reported by other biopharmaceutical companies for key growth assets or newly launched therapies.